financing, and financing saw multiple financing and BD deals in the AI biotechnology sector this week. Westlake Omi received strategic investment, accelerating the commercialization of its AI virtual cell platform; Endless Ark raised nearly 100 million yuan in a single month, laying out AI anti-aging drugs. Innovent Biologics licensed CD40L antibodies for overseas marketing with $1.1 billion, setting a BD benchmark in the autoimmune field. In addition, Lide Health, Pinshan Biotech, and others have completed large financings in AI life science instruments and bioprocess consumables, with capital continuing to invest in positive technologies.

---

1. Xihu Oumi Receives Exclusive Strategic Investment from Ruijiang Kangsheng, Accelerating AI Pharmaceutical Implementation

Recently, a hardcore player in the AI protein module track, Xihu Omi officially announced the completion of an exclusive strategic investment from Ruijiang Kangsheng Fund. This transaction marks a landmark event where industrial capital moves away from the AI pharmaceutical hype logic and focuses on the implementation of underlying hardcore technologies , marking the official entry into a rapid commercialization expansion cycle for the domestic “Proteome + AI Virtual Cell” segment.

Westlake Oumi was founded by Professor Guo Tiannan of Westlake University. Unlike most current AI pharmaceutical projects that focus on small molecule generation and single-point target screening, the company targets a dual-core technology path of “proteomics + AI virtual cells,” establishing a full-chain closed-loop diagnosis and treatment from protein mechanism analysis and drug disturbance prediction to clinical companion diagnosis, forming a strong differentiated competitive barrier. Recently, Guo Tiannan’s team published two milestone results in Nature: for the first time, they mapped a highly comprehensive human proteome spatial map, filling a long-standing gap in protein spatial dimension data in previous multi-omics systems, and providing an ultra-high-precision foundational training dataset for AI virtual cell training; Another study proposed for the first time a systematic framework for constructing virtual cells, establishing the world’s first reusable technical standard in this field. Currently, the world’s first full-function virtual cell model based on perturbation proteomics training is about to be published.

Xihu Omi pioneered a unique “soft landing” implementation model, modularly embedding virtual cell capabilities into existing new drug R&D and clinical testing industry ecosystems, significantly lowering the entry barrier for downstream customers. After this round of financing, the company will strengthen its technological foundation, accelerate the scenario implementation of the virtual cell platform in the new drug pipeline, and promote the commercialization of ongoing companion diagnostic products. Investors Ruijiang Investment and Kangsheng Global both stated they will open up their own industrial resources and jointly promote technology transformation.

---

2. Empowered by Technology from the Chinese Academy of Sciences, Shanghai Leixing Laser completes angel round financing

. Recently, Shanghai Leixing Laser Technology Co., Ltd., a core domestic high-performance medical laser light source, officially announced the completion of its angel round financing. This round was exclusively led by Shanghai Huiguang Xihe Venture Capital Partnership, a subsidiary of Zhongke Shenguang. Shanghai Xihe Optics Valley Incubator provides deep empowerment across the entire industry chain including R&D, supply chain, and medical device compliance. The funds raised will mainly be used for iterative upgrades of core high-power light source technologies, expansion of Class 10,000 cleanroom production workshops, and commercialization of medical laser ODM business.

Leixing Laser’s core technology system is based on decades of technical accumulation in the optoelectronics field of the Chinese Academy of Sciences. In March 2023, it was established in the core area of the Yangtze River Delta laser industry cluster in Jiading, Shanghai. The core team includes four PhDs in optoelectronics, with a total team of nearly 40 people. It holds more than twenty independent core patents covering resonant cavity control, high-stability fiber coupling, and multi-band energy efficiency optimization. It has established a fully closed-loop self-developed and self-produced system from core component packaging to complete machine system integration testing. Its existing industrial laser products cover the full wavelength and are suitable for more than ten precision manufacturing scenarios, and have passed batch delivery validation by leading industrial clients.

Building on consolidating its core advantages in industrial lasers, Leixing Laser has built a customized factory that complies with medical device production quality management standards, achieving stable mass production of all categories of medical laser light sources needed for scenarios such as medical aesthetics, minimally invasive surgery, and ophthalmic diagnosis and treatment, with core performance benchmarked against similar products from leading overseas manufacturers. Currently, nearly 90% of the domestic high-end medical laser light source market share is monopolized by overseas manufacturers, leaving a significant gap in domestic substitution.

After this round of financing, Leixing Laser will accelerate product registration and market introduction, promote the localization and popularization of high-end laser light sources, and is expected to fill a gap in the local field and set a benchmark for the local laser industry.

---

3. Baying Technology Completes Tens of Millions in Financing, Collaborates with Huichuang Medical to Expand the Brain Metabolic Imaging Industry

Recently, a rising domestic company specializing in brain metabolic molecular imaging technology, Baying Technology officially disclosed the completion of a multi-million RMB strategic financing round. The exclusive investor in this round is Huichuang Medical, a leading company in brain function diagnosis and treatment. According to official disclosures, the funds raised in this financing will focus on technology iteration of two core product pipelines: the brain-specific positron emission tomography device (brain PET) and research-grade small animal PET, medical device registration and certification, mass production system construction, and market expansion in clinical and scientific research sectors.

Currently, the global brain science industry is entering a period of rapid growth, and the clinical gap for early screening and diagnosis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s continues to widen. As a core technology for visualizing brain metabolic functions, specialized brain PET offers significant advantages over general whole-body PET in terms of stronger scanning specificity, lower radiation dose, and more than 40% reduction in procurement and maintenance costs. For a long time, the core market has been monopolized by importers, making domestic substitution urgent. The sector is entering a period of development dividends driven by both policy and clinical demand.

As a leading domestic enterprise in brain-computer interface and near-infrared brain functional imaging, Huichuang Medical’s investment is a key measure for its full-loop brain disease diagnosis and treatment strategy and to improve the imaging industry ecosystem. The core team of Baying Technology has over ten years of experience in nuclear medicine imaging technology and has mastered independent patents across the entire chain, including detectors and reconstruction algorithms. Going forward, the two parties will break through capital cooperation, deeply linking clinical resource matching and multimodal imaging product joint research to jointly promote the popularization of domestic brain imaging equipment in lower-tier markets, providing foundational support for the independent development of the domestic brain science industry.

---

4. Pinshan Bio secured nearly 100 million RMB in Series A financing, with multiple capital investors participating

On July 19, Pinshan Biotechnology (Shanghai) Co., Ltd., a benchmark domestic company focused on the core upstream domestic substitution track in biomedicine, officially completed a Series A equity financing round totaling nearly 100 million RMB. This round was led by Yifeng Capital, a well-known professional investment institution in the domestic biopharmaceutical sector, with joint participation from three industry-background capital firms deeply rooted in hard technology: Flenn Stream Capital, Xunshang Venture Capital, and Ruixia Investment. The scale set a single-round transaction record for domestic upstream bioprocess consumables startups at the same stage in nearly two years.

As a deep cultivator in the core areas of biomedicine’s “bottleneck,” Pinshan Bio has driven innovation in underlying materials as its core engine. Since its establishment, it has consistently focused on the high-end biopharmaceutical core consumables track, which has long been monopolized by imported manufacturers. It has now independently built three core technology platforms: chromatography porous microsphere media, single-use bioreactor bag core specialty membranes, and continuous flow chromatography integrated kits. Several products under development have entered the pilot pilot compliance verification stage for leading domestic biopharmaceutical companies. Some core parameters have matched or even surpassed similar products from leading overseas manufacturers.

According to disclosures, all funds raised in this round will be used for core production line expansion, compliance verification of pipeline development, and building a global process service system, further reducing the risk of supply chain disruptions for consumables for downstream biopharmaceutical companies and providing highly reliable full-chain process solutions for global biopharmaceutical companies. This information is compiled by Securities Star based on publicly available information and is for industry reference only, not constituting any investment advice.

---

5. Endless Ark raises nearly 100 million yuan in two rounds in one month, positioning itself in the AI anti-aging drug sector

On July 17, AI-driven anti-aging drug R&D star Shenzhen Endless Ark officially disclosed its latest financing progress: the company completed two consecutive rounds of seed and seed+ rounds within one month. The total financing amount has approached 100 million yuan.

The company was registered in May 2024 and completed three independent business lines covering algorithm development, wet experiment validation, and pipeline advancement in just two monthsWith a solid core portfolio, it secured concentrated capital injections from frontline capital: 27-year-old Oxford University PhD in AI and Medicine led by Zhao Simiao, who became founder and CEO, co-founder Zeng Jingkun is a direct disciple of Nobel laureates in physiology or medicine. The core team brings together PhDs and postdocs in cutting-edge synthetic biology and computational biology from top domestic and international universities, and their interdisciplinary combination directly fills the common gap in AI drug development from “algorithm design to bio-implementation.”

On the technology side, the company has independently developed an industry-leading H2P cross-species transfer learning model, building a full-chain “wet dry” R&D loop that can improve the screening efficiency of traditional anti-aging drug targets by more than three times and reduce trial-and-error costs by over 60%. On the pipeline side, it has already laid out eight pipelines targeting core aging markers, pioneering a strategy of integrating pet drugs with human and pet drug mechanisms, quickly completing efficacy validation based on clinical pet scenarios and accelerating the transformation of human anti-aging drugs.

In 2024, global financing in the longevity sector continues to rise, and multi-target interventions have become recognized by academia as the next-generation anti-aging technology route. All funds from this round will be used for pipeline preclinical development. The company has already established business partnerships with several leading pharmaceutical companies, with the core goal being to implement original drugs that can functionally reverse aging.

---

6. Xuanyan Biotech Secures Pre-A Series Investment

from Fudan Sci-Tech and Detong Capital. Shanghai Xuanyan Biotechnology Co., Ltd., focusing on precision oncology diagnosis and treatment, officially announced today the completion of its Pre-A round of financing. This round was jointly invested by Fudan Sci-Tech Innovation Park’s Sci-Tech Innovation Fund and Detong Capital.

As one of the few innovative companies in China with full-chain technology layout, Xuanyan Biotech’s core team has been deeply involved in early cancer screening and AI bioinformatics for many years, relying on over 120,000 real-world full-cycle clinical sample cohorts co-built by top-tier hospitalsIndependently developed multi-omics coupled AI analysis algorithms, built a leading domestic AI new drug target discovery platform, shortened target validation cycles by 62% compared to traditional R&D models, and achieved a specificity breakthrough of 99.3% for its self-developed pan-cancer early screening products. It pioneered a full-chain integrated precision medicine system from target innovation and early screening product development to clinical auxiliary diagnosis, filling the gap in the domestic market segment of the “R&D-Translation-Implementation” closed-loop in this field.

In addition to direct capital injections, this round of financing will also empower Xuanyan Biotech’s deep resource linkage: Fudan Sci-Tech will connect with clinical and research resources from affiliated hospitals and research institutes within the Fudan system, while Detong Capital will introduce implementation scenarios across the biopharmaceutical industry chain. Capital support will accelerate the company’s R&D progress in three major areas: AI innovative drugs, early cancer screening, and clinical auxiliary diagnostics, further solidifying the technical barriers of its precision medicine platform. It also confirms the primary market’s high recognition of the technical strength and commercialization potential of early-stage hardcore biomedicine projects, promoting the widespread adoption of domestic precision diagnosis and treatment technologies.

---

7. Lide Health completes over 100 million yuan in Pre-A+ round strategic financing, focusing on AI life sciences

. Recently, the domestic substitution process of high-end biomanufacturing equipment has made significant progress. Lide Health, dedicated to AI-driven life science instruments and biodigital intelligence platform development, Recently, it officially announced the completion of a Pre-A+ round of strategic financing exceeding 100 million yuan.

This financing was strategically led by Shanghai Yanquan Technology, a wholly-owned subsidiary of Tuojing Technology, a leading domestic semiconductor thin film equipment company. Existing shareholders deeply involved in hard technology, Jiadao Capital and Zhongke Chuangxing, continue to increase their investment. The industrial capital attributes are distinct, and the synergistic empowerment value far exceeds that of ordinary financial financing.

According to disclosures, the funds raised in this round will focus on three main areas: introducing cutting-edge cross-disciplinary talent, expanding production line capacity for high-throughput AI cell intelligent manufacturing equipment, and establishing a nationwide commercialization service network. This will further strengthen the company’s technological competitive barriers in the AI life science instrument digital intelligence platform field, accelerate the full-process domestic independent mass production of core equipment, and address current cell therapy and A common pain point in the industry is the long-term reliance on imports for upstream high-end equipment in synthetic biology.

As a new hardcore player in the field, Lide Health officially began operations in March 2024, completing a full cell industry chain product layout within just 16 months of its establishment: the current team size exceeds 100 people, with R&D personnel accounting for over 60%. Core talents cover interdisciplinary fields such as AI algorithms, precision optomechanics, and cell biotechnology, with over 20 commercialized products covering the entire process of cell separation, culture, and testing. It has established stable cooperation with over 100 leading clients such as innovative drug companies, cell therapy companies, and top research institutes, with cumulative order value approaching 100 million yuan, ranking among the top tier of similar domestic companies in growth speed.

---

8. $1.1 billion! Innovent Biologics Authorizes CD40L Antibody to “Go Global” On

July 14, Innovent Biologics officially announced an exclusive external licensing agreement with the American innovative drug company Spero TherapeuticsThe company will exclusively grant the global development and commercialization rights for its self-developed third-generation Fc silencing anti-CD40L antibody IBI355 outside Greater China, with a total transaction value of $1.1 billion for tiered milestone payments plus tiered sales revenue. It is a landmark large-scale BD deal for China’s self-immune innovation pipeline going overseas in 2026.

This collaboration marks Innovent Biologics’ fourth billion-dollar external licensing deal in 2026, with pipeline output density and quality ranking among the industry’s leaders. Notably, the partner Spero, a U.S.-based biotech company that has just completed its strategic product line transformation, has clearly secured the milestone rights for the core antibiotic product collaboration previously secured from GSK as collateral for special financing, clearing funding barriers for pipeline implementation.

CD40L, as a star target in the field of autoimmunity, faced long-term clinical translation barriers due to safety issues such as thrombosis risk and nonspecific activation of the Fc terminus. IBI355 was upgraded using Innova’s proprietary Fc engineering platform, completely avoiding the safety pain points of the primary molecule. Multiple clinical studies have now been conducted to verify druggability. The pipeline adopts a differentiated approach of “rare diseases + specialty indications” to avoid homogeneous competition. Currently, the global CD40L antibody market is growing at an annual growth rate of over 30%, with vast growth potential.

This transaction broke away from the traditional approach of relying on overseas pharmaceutical giants for overseas expansion, confirming the new trend of “cross-regional ecosystem building and deep biotech-to-biotech collaboration” in the domestic innovative drug industry, directly validating Innovent Biologics’ solid strength in full-chain drug development and technology platform output.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.